Last updated on February 2018

A Study to Evaluate Escalating Doses of AGS62P1 Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)


Brief description of study

The purpose of this study is to evaluate the safety and tolerability of AGS62P1 given at three dosing schedules (Schedule A, every three weeks [Q3W] or Schedule B, every other week of a 4 week cycle [Q2W] or Schedule C once a week for 3 weeks of a 4 week cycle) in subjects with acute myeloid leukemia (AML) and determine the maximum tolerated dose (MTD). In addition, this study will assess the pharmacokinetics (PK), the immunogenicity and the anti-leukemic activity of AGS62P1.

Clinical Study Identifier: NCT02864290

Contact Investigators or Research Sites near you

Start Over

Agensys Clinical Research and Development

Site US00006
Duarte, CA United States
  Connect »

Agensys Clinical Research and Development

Site US00003
Baltimore, MD United States
  Connect »

Agensys Clinical Research and Development

Site US00004
New York, NY United States
  Connect »

Agensys Clinical Research and Development

Site US00001
Houston, TX United States
  Connect »